OrBec(R) Receives Orphan Drug Designation In Australia For The Treatment Of Gastrointestinal Graft-Versus-Host-Disease

DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company, announced today that the Therapeutics Goods Administration (TGA) of Australia has designated orBec(R) as an Orphan Drug for the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GI GVHD) following allogeneic hematopoietic cell transplantation.

More: continued here

Filed under: Cancer on November 27th, 2008